Shots: Grunenthal acquired Averitas Pharma in all stocks transaction, gained the commercialization rights for Qutenza The focus of the acquisition is to expand and strengthen its footprints in the markets of US Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain […]Read More
